Month: May 2020

UAB Ignitis Grupė, (hereinafter – the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000 000 EUR; ISIN codes XS1646530565; XS1853999313.The Company informs that on 4 May 2020 the Bank of Lithuania (hereinafter – the Bank) approved the prices at which the Company will purchase the shares of the subsidiaries Energijos Skirstymo Operatorius, AB (hereinafter – ESO) and Ignitis Gamyba, AB (hereinafter – GEN) at the time of the mandatory share buy-out.The Bank approved the same prices for the mandatory share buy-out as those which were paid during the tender offers. During the mandatory share buy-out EUR 0.880 will be paid for one share of ESO and EUR 0.640 will be paid for one share of GEN.The buy-out of ESO and GEN shares...

UAB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 600 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313.Bendrovė informuoja, kad 2020 m. gegužės 4 d. Lietuvos bankas (toliau – Bankas)  suderino kainas, už kurias Bendrovė supirks jos dukterinių bendrovių AB „Energijos skirstymo operatorius“ (toliau – ESO) ir AB „Ignitis gamyba“ (toliau – GEN) akcijas privalomų akcijų pardavimų metu.Bankas suderino privalomų akcijų pardavimų kainas tokias pačias, kokios buvo mokamos oficialių  siūlymų metu. Už vieną ESO akciją privalomo akcijų pardavimo metu bus mokama 0,880 EUR, už vieną GEN akciją – 0,640 EUR kainą.ESO ir GEN akcijų išpirkimas truks 90 dienų. Apie jo pradžią ESO, GEN ir Bendrovė...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFULPROGRESS OF PRIVATE PLACEMENT OF UP TO 8,000,000 TREASURY SHARES THROUGH AN ACCELERATED BOOK-BUILDING PROCESSPandora experiences strong interest and expects to close the accelerated book-building shortly.ABOUT PANDORAPandora designs, manufactures and markets hand-finished jewellery made from high-quality materials at affordable prices. Pandora jewellery is sold in more than 100 countries through 7,400 points of sale, including more than 2,700 concept stores.​Headquartered in Copenhagen, Denmark, Pandora employs 28,000 people worldwide and crafts its jewellery at two LEED certified...

5 May 2020G4S PLCAPPOINTMENT OF A NEW NON-EXECUTIVE DIRECTORG4S plc, the leading global security company today announces that Michel van der Bel, who retired at the end of March from his role as President of EMEA Region for Microsoft, will join the board of G4S as a non-executive director with effect from 7 May 2020. Mr van der Bel will also become a member of the Remuneration Committee and of the Risk Committee.Commenting on the new appointment, John Connolly, G4S chairman said:“I am delighted to welcome Michel van der Bel to the board of G4S. Michel brings strong technology leadership experience gained in highly international businesses and a deep understanding of digital transformation in varying markets and industries, which will be very valuable to our board as we recognise the growing importance of technology to our strategy going...

RACINE, Wis., May 05, 2020 (GLOBE NEWSWIRE) — Johnson Outdoors Inc. (Nasdaq: JOUT), a leading global innovator of outdoor recreation equipment and technology, today reported lower sales and net income during the Company’s 2020 second fiscal quarter ending March 27, 2020.  Year-to-date revenue and net income compared favorably to the prior year fiscal six-month period.Following a temporary suspension of operations at some of the Company’s locations, on April 22, 2020, the Company resumed production and shipments in its North American operations in compliance with government-ordered procedures and public health safety guidelines for COVID-19.  During the temporary suspension, all facilities were deep-cleaned and sanitized, and strict operating procedures and protocols, consistent with CDC guidelines, were put in place, along with...

Cloud-first and business continuity focus, as well as developer productivity and security enhancements all available in Progress OpenEdge 12.2BEDFORD, Mass., May 05, 2020 (GLOBE NEWSWIRE) — Progress (NASDAQ: PRGS), the leading provider of application development and digital experience technologies, today announced the release of Progress® OpenEdge® 12.2. OpenEdge application development platform customers and partners now benefit from Progress’ efforts to deliver on the market demands for highly available, high-performing and secure applications — all while taking advantage of an agile development environment.“For decades, Progress has provided the technology businesses need to not only run effectively, but to thrive as markets evolve and end-user needs change,” said John Ainsworth, SVP Core Products, Progress. “In a time...

Overskud på 12,2 mio.kr. før skat forrenter egenkapitalen med 10,6 % p.a.Efter et kvartal med høj aktivitet på bolig og realkreditområdet, en stor tilgang af nye kunder og en flot vækst i netto rente- og gebyrindtægter på 5,4 mio.kr. (15 %) falder resultatet som følge af øgede nedskrivninger på udlån og lavere kursreguleringer. Periodens resultat før skat er et overskud på 12,2 mio.kr. mod 18,0 mio. samme periode året før.Attachment2020-08 Periodeoplysning 202003

Bids, sales, cut-off price, pro rata and yield are presented in the table below:           Settlement: 7 May 2020

 No impact from COVID-19 expected on timing of PRIMROSE 1 and 2 and PROLONG trial readouts, enrollment of new patients in EDELWEISS 2 and 3 on temporary holdLinzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month data on track for Q2:20 readoutActively discussing commercial partnership to maximize linzagolix best-in-class potentialOBE022 Phase 2 PROLONG trial results on track for 2H:20YuYuan Bioscience Technology partnership for nolasiban advancing to IND filing in China 2H:20                         GENEVA, Switzerland and BOSTON, MA (May 5, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended March 31, 2020 and provided a...